MetaVia (MTVA)
NASDAQ:MTVA
Want to see MTVA full AI Analyst Report?
Top Page
MetaVia
(NASDAQ:MTVA)
Select Model
Select Model
Rating:43Neutral
Price Target:
$2.00
▲(42.86% Upside)
Action:Reiterated
Date:05/20/26
The score is held down primarily by weak financial performance (no revenue, continued losses and cash burn, and shrinking equity despite low leverage). Technicals are also weak on a longer-term basis (price well below 100/200-day averages with negative MACD), while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Differentiated cardiometabolic pipeline
MetaVia targets very large, structural markets (obesity, MASH) with two distinct mechanisms (dual oxyntomodulin/GLP-1-glucagon and GPR119 agonism). A differentiated pipeline and global patents create durable strategic optionality for partnerships or combination strategies across cardiometabolic care.
Negative Factors
Pre-revenue status
MetaVia has no commercial revenue, so organizational value relies entirely on clinical and regulatory progress. Absence of product cash flows means milestones, partnerships or financing drive viability; this structural dependency increases execution and financing risk over coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated cardiometabolic pipeline
MetaVia targets very large, structural markets (obesity, MASH) with two distinct mechanisms (dual oxyntomodulin/GLP-1-glucagon and GPR119 agonism). A differentiated pipeline and global patents create durable strategic optionality for partnerships or combination strategies across cardiometabolic care.
Read all positive factors
MetaVia (MTVA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.73M
Dividend YieldN/A
Average Volume (3M)3.42M
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue GrowthN/A
EPS Growth83.72%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.03
Shares Outstanding5,164,370
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap-1.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit478.32
Enterprise Value/Ebitda0.53
Forecast
1Y Price Target
$14.00Price Target Upside900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.44
Revenue Forecast (FY)N/A
MetaVia Business Overview & Revenue Model
Company Description
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionalit...
MetaVia Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
56
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -15.00K | -19.00K | -24.00K | -7.00K | -28.00K | -72.00K |
| EBITDA | -13.52M | -13.69M | -28.79M | -15.88M | -11.76M | -15.24M |
| Net Income | -13.13M | -12.97M | -27.59M | -12.47M | -13.97M | -15.28M |
Balance Sheet | ||||||
| Total Assets | 14.39M | 69.12M | 16.26M | 22.78M | 33.53M | 16.80M |
| Cash, Cash Equivalents and Short-Term Investments | 13.73M | 10.28M | 16.02M | 22.43M | 33.36M | 16.39M |
| Total Debt | 194.00K | 210.00K | 136.00K | 203.00K | 0.00 | 71.00K |
| Total Liabilities | 5.32M | 63.79M | 8.33M | 6.10M | 11.78M | 2.20M |
| Stockholders Equity | 9.07M | 5.33M | 7.93M | 16.68M | 21.75M | 14.60M |
Cash Flow | ||||||
| Free Cash Flow | -15.15M | -15.70M | -24.72M | -10.85M | -11.71M | -15.14M |
| Operating Cash Flow | -15.14M | -15.70M | -24.71M | -10.80M | -11.71M | -15.13M |
| Investing Cash Flow | -2.00K | -2.00K | -8.00K | -50.00K | 8.00K | -586.00K |
| Financing Cash Flow | 17.69M | 9.96M | 18.30M | -80.00K | 28.68M | 22.03M |
MetaVia Technical Analysis
Positive
1.40
Price Trends
1.39
Positive
2.59
Negative
5.87
Negative
Market Momentum
-0.04
Negative
66.86
Neutral
46.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTVA, the sentiment is Positive. The current price of 1.4 is above the 20-day moving average (MA) of 1.37, above the 50-day MA of 1.39, and below the 200-day MA of 5.87, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 66.86 is Neutral, neither overbought nor oversold. The STOCH value of 46.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MTVA.
MetaVia Risk Analysis
MetaVia disclosed 66 risk factors in its most recent earnings report. MetaVia reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MetaVia Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $74.70M | -1.54 | -14.39% | ― | 1.18% | 83.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $14.47M | -0.18 | -77.46% | ― | ― | 55.15% | |
45 Neutral | $22.46M | -2.51 | 9999.00% | ― | ― | -1753.64% | |
43 Neutral | $5.73M | -0.38 | -229.48% | ― | ― | 83.72% |
* Healthcare Sector Average
MTVA
MetaVia
2.89
-6.74
-69.99%
PMN
ProMIS Neurosciences
10.60
-1.81
-14.56%
CTXR
Citius Pharmaceuticals
0.58
-0.10
-14.83%
RLYB
Rallybio
14.19
11.58
444.51%
KAPA
Kairos Pharma, Ltd.
0.48
-0.10
-17.30%
MetaVia Corporate Events
Business Operations and StrategyProduct-Related Announcements
MetaVia Showcases Key Cardiometabolic Data at ADA 2026
Positive
May 18, 2026
MetaVia Inc., a clinical-stage biotechnology company specializing in therapies for cardiometabolic diseases such as obesity and MASH, is advancing a pipeline led by DA-1726, a dual GLP-1/glucagon oxyntomodulin analog, and vanoglipel, a GPR119 agon...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
MetaVia Highlights Strong DA-1726 Phase 1 Weight-Loss Data
Positive
May 14, 2026
MetaVia Inc., a clinical-stage biotech focused on cardiometabolic diseases, is advancing two lead programs: DA-1726 for obesity and vanoglipel for MASH, supported by extensive global patent portfolios licensed from Dong-A ST. The company’s p...
Business Operations and StrategyProduct-Related Announcements
MetaVia to Present New DA-1726 Obesity Data at EASL
Positive
May 11, 2026
MetaVia Inc., a Nasdaq-listed clinical-stage biotech based in Cambridge, Mass., is developing DA-1726 for obesity and vanoglipel for MASH, aiming to reshape treatment of cardiometabolic diseases with gut hormone-based therapeutics. DA-1726, an oxy...
Business Operations and StrategyProduct-Related Announcements
MetaVia Advances DA-1726 Obesity Trial With First Patient
Positive
Apr 10, 2026
On April 10, 2026, MetaVia Inc. announced it had dosed the first patient in Part 3 of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog targeting GLP-1 and glucagon receptors for the treatment of obesity. The new 16-week study seg...
Business Operations and Strategy
MetaVia Updates Investor Strategy for Obesity and MASH
Positive
Mar 26, 2026
On March 26, 2026, MetaVia Inc. reported that it had posted an updated investor presentation outlining its strategy to address obesity and MASH, two large and rapidly expanding therapeutic markets with projected annual sales in the tens of billion...
Business Operations and StrategyProduct-Related Announcements
MetaVia Advances DA-1726 Obesity Drug into Phase 1 Part 3
Positive
Mar 18, 2026
On March 18, 2026, MetaVia Inc. announced that an Institutional Review Board at Clinical Pharmacology of Miami approved Part 3 of its Phase 1 clinical trial for DA-1726, its lead GLP-1 and glucagon dual agonist for obesity. The new 16-week study w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.